Clinical trial · Observational
Myeloproliferative Neoplasms: an In-depth Case-control Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
There is a paucity of data on the aetiology of myeloproliferative neoplasms (MPNs). The investigators conducted a systematic review of the literature which identified several cohort and case-control studies that have investigated a wide range of potential medical, environmental and occupational risk factors. However, these studies have been limited by a wide variation in case definition and small sample sizes limiting the potential to detect modest risk differences between cases and controls. The research group propose an exploratory case-control study of 100 patients with classic MPNs and 200 controls to determine the optimal methods for roll out of this study to a multi-centred UK-based case-control study that will investigate the aetiology of MPN subtypes. The objectives of the study are to evaluate recruitment procedures, response rates and the development of a telephone administered questionnaire. The findings of this exploratory study will form the basis of a protocol for a large United Kingdom (UK)-wide case-control study of MPNs.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
| Primary Myelofibrosis | Primary Myelofibrosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Methodological compensation | Other | — | UNRESOLVED |
| Methodological pens | Other | — | UNRESOLVED |
| Methodological trolley tokens | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Myeloproliferative neoplasm case
- description
- Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria. Exclusion Criteria * younger than 18 years old. * where the clinician/General Practitioner (GP) does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate. We will assess whether a pen (branded, non-branded or none), a £10 cheque and/or a charity branded trolley token will affect uptake rates in the study.
- interventionNames
- Other: Methodological pens
- Other: Methodological compensation
- Other: Methodological trolley tokens
- label
- General Practice Control
- description
- GP controls will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender. The following patient groups will be excluded. Those: * younger than 18 years old. * where the clinician/GP does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate. We will assess whether a pen (branded, non-branded or none), a £10 cheque (at study completion) and/or a charity branded trolley token will affect uptake rates in the study.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Myeloproliferative neoplasm cases Inclusion criteria: * Clinical diagnosis of polycythemia vera, essential thrombocythaemia or primary myelofibrosis based on the WHO diagnostic criteria. * Aged 18 years or older. Exclusion Criteria: * younger than 18 years old. * where the clinician/General Practitioner (GP) does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate General Practice Controls Inclusion Criteria: * Randomly selected, frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender. * Aged 18 years or older. Exclusion Criteria: * younger than 18 years old. * where the clinician/GP does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate. Relative/Friend Controls Inclusion Criteria: * Non-blood relative/friend of a case participating in the study. * Aged 18 years or older. Exclusion Criteria: * younger than 18 years old. * where the clinician/GP does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate.
References
Publications (3)
- BACKGROUNDAnderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol. 2012 Feb;87(2):175-82. doi: 10.1002/ajh.22212. Epub 2011 Nov 11. PMID 22076943
- BACKGROUNDJames G, McMullin MF, Duncombe AS, Clarke M, Anderson LA. The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples. Ann Hum Genet. 2018 Mar;82(2):114-118. doi: 10.1111/ahg.12227. Epub 2017 Oct 27. PMID 29076129
- RESULTAnderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015 Oct;90(10):864-70. doi: 10.1002/ajh.24098. Epub 2015 Sep 10. PMID 26113113